Innoviva Aktie News

d'Esparbes to lead Antheia's financial strategy as the company continues its global expansionand commercialization MENLO PARK, Calif. , Oct. 21, 2025 /PRNewswire/ --  Antheia , the pharmaceutical ingredient manufacturer transforming essential medicine supply chains, today announced the appointment of Eric d'Esparbes as Chief Financial Officer.

WALTHAM, Mass.--(BUSINESS WIRE)--Innoviva Specialty Therapeutics, a subsidiary of Innoviva, Inc. (NASDAQ: INVA), will share new data on zoliflodacin during the Infectious Disease Society of America's IDWeek 2025 annual meeting in Atlanta, GA, October 19-22, 2025. Zoliflodacin is a first-in-class oral antibiotic being developed for the treatment of uncomplicated gonorrhea. Three sets of data wil...

WALTHAM, Mass.--(BUSINESS WIRE)--Innoviva Specialty Therapeutics, a subsidiary of Innoviva, Inc. (NASDAQ: INVA), today announced that it will deliver data from six presentations at IDWeek 2025, including clinical data, pharmacokinetic-pharmacodynamic (PK-PD) analyses, and microbiologic surveillance from its growing portfolio of antibiotics and critical care medicines. IDWeek will be held in Atl...

Innoviva, Inc. (NASDAQ:INVA ) Citi's Biopharma Back to School Conference September 2, 2025 1:45 PM EDT Company Participants Pavel Raifeld - CEO & Director Conference Call Participants Jason Jun - Citi Presentation Jason Jun Well, thanks for joining, everyone. Today with us, we have Pavel Raifeld, the CEO of Innoviva.

BURLINGAME, Calif.--(BUSINESS WIRE)--Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or the “Company”), a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics (“IST”), and a portfolio of strategic investments in healthcare assets, today announced that management will participate in the following u...

WALTHAM, Mass.--(BUSINESS WIRE)--Prix Galien Award 2025.

Innoviva (INVA -1.03%), a pharmaceutical company specializing in royalties and specialty therapeutics, reported second-quarter earnings on August 6, 2025. The company announced earnings per share (GAAP) of $0.77 on $100.3 million in revenue.

BURLINGAME, Calif.--(BUSINESS WIRE)--Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or the “Company”), a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics (“IST”), and a portfolio of strategic investments in healthcare assets, today reported financial results for the second quarter ended June ...